Research summary ·
Survival and prognosis of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumours: a systematic review and meta-analysis.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This review looked at survival in malignant peripheral nerve sheath tumour (MPNST). MPNST is a rare, aggressive sarcoma. Some cases occur in people with neurofibromatosis type 1 (NF1). Others occur on their own. The team compared survival between these groups. Several earlier studies pointed to worse survival with NF1. The search ran on 12 October 2024. 4,394 studies were screened and 36 were included.
What they found
A meta-analysis named NF1 status as a risk factor for survival. The treatment is challenging when surgery is not possible. Survival rates varied between studies. The 5-year overall survival stayed poor in general. 15 studies showed significantly worse survival for NF1-linked tumours. A few studies showed worse survival for sporadic tumours. None of these differences was significant.
What it means for patients
The authors say NF1-linked MPNST has worse survival. The comparison is with sporadic MPNST. This conclusion rests on 36 studies.
Why it is not certain yet
The abstract notes that NF1 status alone may not be the cause of poor outcomes. Tumours in NF1 are often larger. They are harder to remove by surgery. Survival rates varied between studies.
Source
Survival and prognosis of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumours: a systematic review and meta-analysis.
PubMed · PMID 42310813We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Sarcoma publications